Kairos Pharma
Kairos Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to overcome cancer drug resistance and reverse cancer-induced immune suppression. Their mission is to push the boundaries of medical science and improve outcomes for patients facing challenging diseases. They focus on targeted therapies such as ENV105, which inhibits CD105 to restore the effectiveness of standard cancer treatments, and other technologies aimed at modulating immune responses and overcoming resistance mechanisms. The company is actively progressing through clinical trials, including Phase 2 in prostate cancer and Phase 1 in lung cancer, with a strategic focus on transforming cancer care and extending patient lives.
Industries
Nr. of Employees
small (1-50)
Kairos Pharma
Patents
Products
Antibody therapeutic that inhibits CD105/BMP signaling to reverse drug resistance
A monoclonal antibody therapeutic designed to bind CD105 (endoglin) and inhibit BMP signaling, with the objective of restoring sensitivity to standard cancer drugs; advanced into Phase I/II clinical trials.
Small‑molecule GITR ligand modulators (agonist and antagonist)
Small molecules designed to either agonize or antagonize the GITR ligand to modulate effector and regulatory T cell populations for cancer and autoimmune indications.
Activated/expanded T‑cell therapy targeting glioblastoma cancer stem cells
Adoptive T‑cell therapy product generated ex vivo against glioblastoma cancer stem cell antigens; program has an IND cleared by the FDA.
NF‑κB pathway small‑molecule inhibitor
Small‑molecule candidate that inhibits relA nuclear translocation in the NF‑κB pathway, with preclinical activity shown in tumor models.
Macrophage‑reprogramming cyclic peptide
Cyclic peptide designed to inhibit IL‑4/IL‑13 receptor signaling on macrophages and reverse pro‑tumor macrophage polarization.
Mitochondrial DNA–targeting agent to reverse chemotherapy resistance
Therapeutic approach that targets tumor mitochondrial DNA mechanisms associated with resistance to taxane‑class chemotherapies.
Antibody therapeutic that inhibits CD105/BMP signaling to reverse drug resistance
A monoclonal antibody therapeutic designed to bind CD105 (endoglin) and inhibit BMP signaling, with the objective of restoring sensitivity to standard cancer drugs; advanced into Phase I/II clinical trials.
Small‑molecule GITR ligand modulators (agonist and antagonist)
Small molecules designed to either agonize or antagonize the GITR ligand to modulate effector and regulatory T cell populations for cancer and autoimmune indications.
Activated/expanded T‑cell therapy targeting glioblastoma cancer stem cells
Adoptive T‑cell therapy product generated ex vivo against glioblastoma cancer stem cell antigens; program has an IND cleared by the FDA.
NF‑κB pathway small‑molecule inhibitor
Small‑molecule candidate that inhibits relA nuclear translocation in the NF‑κB pathway, with preclinical activity shown in tumor models.
Macrophage‑reprogramming cyclic peptide
Cyclic peptide designed to inhibit IL‑4/IL‑13 receptor signaling on macrophages and reverse pro‑tumor macrophage polarization.
Mitochondrial DNA–targeting agent to reverse chemotherapy resistance
Therapeutic approach that targets tumor mitochondrial DNA mechanisms associated with resistance to taxane‑class chemotherapies.
Services
Partnerships with medical centers to support multi‑center Phase I/II clinical trials and translational research collaborations.
Management and licensing of patents and academic‑sourced IP to support therapeutic development.
Partnerships with medical centers to support multi‑center Phase I/II clinical trials and translational research collaborations.
Management and licensing of patents and academic‑sourced IP to support therapeutic development.
Expertise Areas
- Immunotherapy development
- Clinical trial management (Phase I/II)
- Mechanisms of cancer drug resistance
- Adoptive cell therapy and T‑cell engineering
Key Technologies
- Monoclonal antibody therapeutics (CD105/endoglin targeting)
- Small‑molecule immunomodulators (GITR ligand modulators)
- Adoptive/activated T‑cell therapy
- Peptidomimetics and cyclic peptide inhibitors